Key points are not available for this paper at this time.
Design
Editorial
Answers are grounded in this paper and cite their sources.
This editorial introduces reviews and trial updates on advanced heart failure treatments (LVADs) and revascularization strategies (CABG vs PCI) in complex coronary artery disease.
![Graphic][1] Advanced heart failure is a growing epidemic as the available treatment options currently are palliative in nature. Indeed, although life expectancy has been improved thanks to modern medical treatment of chronic heart failure1,2 and thanks to devices such as biventricular pacemakers3 and implantable cardioverter defibrillators4 as outlined in the most recent ESC Guidelines,5 the clinical outcome eventually remains dismal. The most effective treatment option, cardiac transplantation, is still reserved for highly selected6 and younger patients7 with advanced heart failure. Recently, left ventricular assist devices have led to improved quality of life and long-term survival for patients diagnosed with this devastating condition. In their Clinical Review ‘ Left ventricular assist devices: current controversies and future directions ’,8 Mark Slaughter and colleagues from the University of Louisville in Kentucky, USA update previous reviews and summarize the history and clinical outcomes of left ventricular assist devices. They also focus on the current controversies and issues facing left ventricular assist device therapy. Finally, future direction for the role of left ventricular assist devices in the treatment of end-stage heart failure either as transition or as destination therapy is discussed. The most important cause of end-stage heart failure is coronary artery disease. Whether percutaneous coronary intervention or bypass surgery is more efficacious in preventing reinfarction, remodelling, and death is a continuing debate. In an ESC Clinical Trial Update FAST TRACK ‘ Comparative efficacy of coronary artery bypass surgery vs. percutaneous coronary intervention in patients with diabetes and multivessel coronary artery disease with or without chronic kidney disease ’ Usman Baber and colleagues from the Icahn School of Medicine at Mount Sinai in New York City investigate the optimal approach of coronary revascularization among patients with diabetes mellitus and multivessel coronary artery disease complicated by chronic kidney … [1]: /embed/inline-graphic-1.gif
No takes yet. Share an insight, caveat, or question.
Thomas F. Lüscher (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: